Menu

Pathway to A Cure

Join our effort to detect myeloma sooner, customize treatment, conduct worldwide data analysis and clinical trials, and unlock the Pathway to A Cure.

Join the Conversation

Multiple myeloma is the second most common blood cancer. Yet the majority of patients have never heard of it until they are told they have the disease.

Make A Difference

Your donation today can make the difference for multiple myeloma patients in your community and around the world.

Black Swan Research Initiative Updates

  • iStop MM® gets off to a fast start

    The IMF team just returned from the exciting iStopMM kickoff meeting held September 26-27th at the

  • Precision Oncology and the Cancer Moonshot: Where Do We Stand?

    There have been recent commentaries on the prospects and potential for both what is called

  • Four Important Ways Iceland’s iStopMM Research Project Will Help Myeloma Patients Globally

    The iStopMM research project is about to get started in Iceland. It is supported through the

  • Preview of the Black Swan Research Initiative’s First US Cure Trial

    Dr. Shaji Kumar shares the details of the upcoming US ASCENT “Cure Trial” in a video interview

  • Understanding the Nature of MRD-Positive Myeloma

    A study in the journal Blood reports for the first time the biological features of MRD (minimal

    %d bloggers like this: